Literature DB >> 4063178

Involvement of macrophages in the pathology of toxic epidermal necrolysis.

J C Roujeau, L Dubertret, S Moritz, H Jouault, M Heslan, J Revuz, R Touraine.   

Abstract

In toxic epidermal necrolysis (TEN), as in the 'epidermal type' of erythema multiforme, the necrotic epidermis is infiltrated with mononuclear cells. We studied the epidermal infiltrate in seven cases of TEN. About half the cells obtained from pieces of cleaved epidermis dissociated by trypsin were non-epithelial. On cytologic analysis, 80% of these foreign cells exhibited markers of macrophages, 15% were granulocytes and only 5% were lymphocytes (almost exclusively OKT8 T lymphocytes). Semi-thin sections of early prenecrotic lesions showed exocytosis of mononuclear cells within the epidermis with features of satellite cell necrosis and formation of colloid bodies. Almost all these mononuclear cells were macrophages as evidenced by endogenous peroxidase-positive granules. These findings suggest that some kind of macrophage-mediated cytotoxicity may play a role in the necrosis of epidermal cells during TEN.

Entities:  

Mesh:

Year:  1985        PMID: 4063178     DOI: 10.1111/j.1365-2133.1985.tb02356.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  3 in total

1.  Early pathological features of the cornea in toxic epidermal necrolysis.

Authors:  G P Williams; H S Mudhar; M Leyland
Journal:  Br J Ophthalmol       Date:  2007-03-14       Impact factor: 4.638

2.  New insights in toxic epidermal necrolysis (Lyell's syndrome): clinical considerations, pathobiology and targeted treatments revisited.

Authors:  Philippe Paquet; Gérald E Piérard
Journal:  Drug Saf       Date:  2010-03-01       Impact factor: 5.606

3.  Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study.

Authors:  F Lebargy; P Wolkenstein; M Gisselbrecht; F Lange; J Fleury-Feith; C Delclaux; E Roupie; J Revuz; J C Roujeau
Journal:  Intensive Care Med       Date:  1997-12       Impact factor: 17.440

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.